RETA — Reata Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeLarge Cap
- $6.52bn
- $6.27bn
- $2.22m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2,670.99 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -80.79% | ||
| Return on Equity | n/a | ||
| Operating Margin | -21533.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 53.59 | 26.52 | 9.02 | 11.49 | 2.22 | 54.33 | 362.64 | -45.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on identifying, developing, and commercializing therapies. The Company concentrates on small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. The Company's first product, SKYCLARYS (omaveloxolone), is used for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. It is also engaged in developing cemdomespib, the lead product candidate from its Hsp90 modulator program, in neurological indications and Nrf2 activators for neurological diseases. Omaveloxolone activates the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation, in nonclinical models. Its Nrf2 activators are applicable to both rare diseases, such as Huntington's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive multiple sclerosis, and others.
Directors
- J. Warren Huff CHM (67)
- Manmeet Soni PRE (43)
- Dawn Bir EVP (50)
- Colin Meyer EVP (42)
- Michael Wortley EVP (73)
- Bhaskar Anand CAO (44)
- Martin Edwards IND (65)
- William McClellan IND (61)
- R. Kent McGaughy IND (49)
- Jack Nielsen IND (57)
- Christy Oliger IND (51)
- William Rose IND (52)
- Shamim Ruff IND (61)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- March 11th, 2002
- Public Since
- May 26th, 2016
- No. of Shareholders
- 467
- No. of Employees
- 321
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 37,551,442
- Address
- 5320 Legacy Dr, PLANO, 75024-3127
- Web
- https://www.reatapharma.com/
- Phone
- +1 9728652219
- Auditors
- Ernst & Young LLP
Upcoming Events for RETA
Q3 2023 Reata Pharmaceuticals Inc Earnings Release
Similar to RETA
89bio
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Reata Pharmaceuticals share price?
As of Today at 01:19 UTC, shares in Reata Pharmaceuticals are trading at $106.48. This share price information is delayed by 15 minutes.
How has the Reata Pharmaceuticals share price performed this year?
Shares in Reata Pharmaceuticals last closed at $106.48 and the price had moved by +244.37% over the past 365 days. In terms of relative price strength the Reata Pharmaceuticals share price has outperformed the S&P500 Index by +195.64% over the past year.
What are the analyst and broker recommendations for Reata Pharmaceuticals?
The overall consensus recommendation for Reata Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Reata Pharmaceuticals dividend yield?
Reata Pharmaceuticals does not currently pay a dividend.
Does Reata Pharmaceuticals pay a dividend?
Reata Pharmaceuticals does not currently pay a dividend.
When does Reata Pharmaceuticals next pay dividends?
Reata Pharmaceuticals does not currently pay a dividend.
How do I buy Reata Pharmaceuticals shares?
To buy shares in Reata Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Reata Pharmaceuticals?
As of the previous close price of $106.48, shares in Reata Pharmaceuticals had a market capitalisation of $3.98bn.
Where are Reata Pharmaceuticals shares listed?
Here are the trading details for Reata Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RETA
What kind of share is Reata Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Reata Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Reata Pharmaceuticals share price forecast for 2023?
The analyst consensus target price for shares in Reata Pharmaceuticals is $119.24. That is 11.98% above the last closing price of $106.48.
Analysts covering Reata Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$10.49 for the next financial year.
What is the trend in the Reata Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Reata Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +132.25%.
As of the last closing price of $106.48, shares in Reata Pharmaceuticals were trading +59.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Reata Pharmaceuticals PE Ratio?
The Reata Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $106.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Reata Pharmaceuticals?
Reata Pharmaceuticals' management team is headed by:
- J. Warren Huff - CHM
- Manmeet Soni - PRE
- Dawn Bir - EVP
- Colin Meyer - EVP
- Michael Wortley - EVP
- Bhaskar Anand - CAO
- Martin Edwards - IND
- William McClellan - IND
- R. Kent McGaughy - IND
- Jack Nielsen - IND
- Christy Oliger - IND
- William Rose - IND
- Shamim Ruff - IND